Follow-up of the Study 971-ONC-0028-080: "Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study.

Trial Profile

Follow-up of the Study 971-ONC-0028-080: "Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2011

At a glance

  • Drugs Exemestane; Megestrol
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 11 Mar 2011 Actual end date changed from 1 Feb 2010 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 16 Nov 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top